+86 13332949210
info@xihobattery.com
Xiho
Jun 04 2026
SHANGHAI / JINGMEN – The 93rd China International Medical Equipment Fair (CMEF) Spring Edition opened on April 9, 2026. At the event, EVE Energy launched its latest medical-grade innovation: the CR123AP battery, engineered to deliver high-performance, reliable power for next-generation healthcare equipment.
Product Philosophy and Industry Background
EVE Energy's approach to medical batteries is guided by a unique philosophy: treating each cell as a living entity that demands care and precision. With over two decades of expertise, the company has developed a complete product ecosystem serving implantable devices, in-vitro diagnostics, and emergency medical equipment. As the healthcare industry evolves—with AEDs expanding into diverse public settings and surgical tools requiring higher performance—demands for more reliable, adaptable, and environmentally responsible power sources continue to grow. The CR123AP is EVE Energy’s response to these critical needs.
Core Technological Advantages
The CR123AP addresses key limitations of traditional medical batteries, offering four significant performance improvements:
- Extended Service Life: Through advanced high‑pulse output technology, the battery achieves a cycle life that exceeds industry averages, enhancing the long‑term value and uptime of medical devices.
- Superior High‑Rate Performance: It provides a stable, high‑rate pulse platform, ensuring precise and consistent activation to meet the rigorous demands of modern medical systems.
- Exceptional Low‑Temperature Operation: The battery delivers reliable pulse output capability even at –20 °C—performance that is up to 5.92 times better than competing products—enabling dependable use in cold environments.
- Sustainable Manufacturing Process: Utilizing a proprietary dry‑electrode production method, the CR123AP reduces carbon emissions and solvent use, aligning high performance with environmental stewardship.
Proprietary Dry-Electrode Technology
EVE Energy continuously refines its battery technology, focusing on reducing self‑discharge, extending operational lifespan, and broadening usable temperature ranges. The implementation of AI‑powered intelligent inspection and fully digitalized manufacturing lines ensures exceptional consistency, safety, and reliability in every cell produced—a non‑negotiable standard for life‑supporting and emergency medical equipment.
Global Production and Availability
Development of the CR123AP began in 2025, with mass production scheduled for 2026. The battery will be manufactured simultaneously at EVE Energy’s production bases in Jingmen, China, and Penang, Malaysia. This dual‑source, global manufacturing strategy ensures a stable supply chain to serve medical device manufacturers worldwide, supporting the ongoing advancement and iteration of healthcare technologies. Through sustained innovation and a market‑driven approach, EVE Energy strengthens its role as a key enabler in the medical sector, providing intelligent, green power solutions that safeguard health and enable a better life.
Inquiry more product details from the : Lithium Ion Battery Manufacturers
WhatsApp/Wechat/Mobile: +86 13332949210
Email: info@xihobattery.com
Website: www.xihopower.com
WhatsApp/Wechat/Mobile: +86 13332949210
Email: info@xihobattery.com
Website: www.xihopower.com
